---

$3.82

-0.0950 ( -2.93% ) 13.3K

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-09-12	Buy	1250.00	Stengone Carmine N.
2024-09-11	Buy	3000.00	Shapiro Aron
2024-08-20	Buy	1250.00	Walters-Hoffert Lisa
2024-08-19	Buy	5000.00	TYLE PRAVEEN
2024-08-15	Buy	2000.00	Tosca Melissa
2024-07-03	Sale	-1778.00	Shapiro Aron
2024-07-03	Sale	-7355.00	Daniels Eric Joseph
2024-07-03	Sale	-1778.00	Hollander David
2024-07-03	Sale	-1778.00	Walters-Hoffert Lisa
2024-07-03	Sale	-1778.00	Parsons Erin

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.